The 1995 Uk Medicines Control Agency ruling on the prohibition of advertising of topical products for the treatment of arthritic pain has been contested by the Proprietary Association of Great Britain, which represents the non-prescription drug industry, the prescribing subcommittee of the British Medical Council general Medical Services Committee, the Consumers' Association and the National Consumers' Council.
They have all said that the original consultation was confusing, and that treatment of mild to moderate arthritic pain should be offered to suffers, following a doctor's diagnosis.
On March 22, the MCA issued another consultation (MLX 223), allowing the symptomatic relief of sprains and strains and pain due to nonserious arthritis and rheumatism conditions. The PAGB says while this is a major step, it is still uncertain how "nonserious" wil be interpreted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze